» Articles » PMID: 32928306

Functional Enhancement Strategies for Immunomodulation of Mesenchymal Stem Cells and Their Therapeutic Application

Overview
Publisher Biomed Central
Date 2020 Sep 15
PMID 32928306
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have recently been considered a promising alternative treatment for diverse immune disorders due to their unique biomedical potentials including the immunomodulatory property and ability to promote tissue regeneration. However, despite many years of pre-clinical studies in the research field, results from clinical trials using these cells have been diverse and conflicting. This discrepancy is caused by several factors such as poor engraftment, low survival rate, and donor-dependent variation of the cells. Enhancement of consistency and efficacy of MSCs remains a challenge to overcome the current obstacles to MSC-based therapy and subsequently achieve an improved therapeutic outcome. In this review, we investigated function enhancement strategies by categorizing as preconditioning, genetic manipulation, usage of supportive materials, and co-administration with currently used drugs. Preconditioning prior to MSC application makes up a large proportion of improvement strategies and preconditioning reagents include bioactive substances (cytokines, growth factors, and innate immune receptor agonists), hypoxia, and modification in culture method. With the piled results from previous studies using each method, disease- or patient-specific therapy has become more important than ever. On the other hand, genetic manipulation targeting therapeutic-associated factors or co-administration of biocompatible materials has also arisen as other therapeutic strategies. Thus, we summarized several specialized tactics by analyzing up-to-date results in the field and proposed some promising enhancement methods to improve the clinical outcomes for MSC therapy.

Citing Articles

Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity.

Valencia J, Yanez R, Muntion S, Fernandez-Garcia M, Martin-Rufino J, Zapata A Front Immunol. 2025; 16:1473788.

PMID: 40034706 PMC: 11872697. DOI: 10.3389/fimmu.2025.1473788.


Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.

Li L, He Y, Zhao J, Yin H, Feng X, Fan X Clin Rev Allergy Immunol. 2025; 68(1):21.

PMID: 39982546 DOI: 10.1007/s12016-025-09030-9.


Secretome of human amniotic membrane stem cells promote recovery and testicular functions through modulating pathway in mice testicular torsion: An experimental study.

Esfehani R, Khadivi F, Valipour J, Shabani M, Ramesh M, Javanbakht P Int J Reprod Biomed. 2025; 22(10):821-836.

PMID: 39906090 PMC: 11788658. DOI: 10.18502/ijrm.v22i10.17670.


Engineered Mesenchymal Stem Cells as Treatment for Cancers: Opportunities, Clinical Applications and Challenges.

Shamsul Kamal A, Fakiruddin K, Bobbo K, Ling K, Vidyadaran S, Abdullah S Malays J Med Sci. 2024; 31(5):56-82.

PMID: 39416732 PMC: 11477465. DOI: 10.21315/mjms2024.31.5.5.


Recent Advances in Nanomaterials for Modulation of Stem Cell Differentiation and Its Therapeutic Applications.

Kim C, Koo K, Kim H, Kim T Biosensors (Basel). 2024; 14(8).

PMID: 39194636 PMC: 11352443. DOI: 10.3390/bios14080407.


References
1.
Cheng W, Su J, Hu Y, Huang Q, Shi H, Wang L . Interleukin-25 primed mesenchymal stem cells achieve better therapeutic effects on dextran sulfate sodium-induced colitis via inhibiting Th17 immune response and inducing T regulatory cell phenotype. Am J Transl Res. 2017; 9(9):4149-4160. PMC: 5622258. View

2.
Redondo-Castro E, Cunningham C, Miller J, Martuscelli L, Aoulad-Ali S, Rothwell N . Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro. Stem Cell Res Ther. 2017; 8(1):79. PMC: 5393041. DOI: 10.1186/s13287-017-0531-4. View

3.
Hu Y, Liu S, Zhu B . CRISPR/Cas9-Induced Loss of Keap1 Enhances Anti-oxidation in Rat Adipose-Derived Mesenchymal Stem Cells. Front Neurol. 2020; 10:1311. PMC: 7040357. DOI: 10.3389/fneur.2019.01311. View

4.
Chinnadurai R, Copland I, Patel S, Galipeau J . IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol. 2014; 192(4):1491-501. DOI: 10.4049/jimmunol.1301828. View

5.
Kim H, Shin T, Lee B, Yu K, Seo Y, Lee S . Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology. 2013; 145(6):1392-403.e1-8. DOI: 10.1053/j.gastro.2013.08.033. View